Diagnostic performance of imaging techniques for detecting of local recurrence after prostate brachytherapy
Cancer/Radiothérapie. 2020-07-01; 24(4): 323-331
DOI: 10.1016/j.canrad.2020.03.008
Read on PubMed
Karahissarlian V(1), Sargos P(2), Blais E(1), Cazeau AL(3), Fontes F(4), Petitpierre F(5), Rigou G(6), De Vaugelade C(3), Mariey A(3), Hindié E(7), Thomas L(1).
Author information:
(1)Department of Radiation Oncology, institut Bergonié, 229, cours de l’Argonne,
33076 Bordeaux cedex, France.
(2)Department of Radiation Oncology, Jewish General Hospital, 3755,
Côte-Sainte-Catherine road, Montreal, Quebec H3T 1E2, Canada. Electronic address:
.
(3)Department of Nuclear Medicine, institut Bergonié, 229, cours de l’Argonne,
33076 Bordeaux cedex, France.
(4)Interventional Radiology, nouvelle clinique Bel-Air, 138, avenue de la
République, 33000 Bordeaux, France.
(5)Interventional Radiology, service d’imagerie diagnostique et thérapeutique de
l’adulte, hôpital Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex,
France.
(6)IRMBA, centre de radiologie et d’imagerie médicale, hôpital d’Arcachon, avenue
Jean-Hameau, 33164 La Teste-de-Buch, France.
(7)Department of Nuclear Medicine, hôpital Haut-Lévêque, CHU de Bordeaux, avenue
de Magellan, 33600 Pessac, France.
PURPOSE: The purpose of this study was to evaluate MRI and fluorocholine PET/CT
diagnostic performances for the detection of local recurrence following prostate
brachytherapy for localised prostate cancer.
MATERIAL AND METHODS: In this single-centre study, we retrospectively reviewed
data from 21 patients treated by brachytherapy for localised prostate cancer and
diagnosed with biochemical recurrence according to Phoenix Criteria, who
underwent MRI and fluorocholine PET/CT. We included patients with local relapse
suspicion according to imaging exams, with biopsy for the final assessment of
local recurrence. Patient analysis data were supplemented by segment analysis
using an 8-segment model.
RESULTS: The fluorocholine PET/CT was positive for 81% and negative for 19% of
patients. The sensitivity and specificity were 92% and 33% with diagnosis
accuracy of 67%. The MRI was positive for 57% and negative for 43% of patients.
The sensitivity and specificity were 67% and 56% with diagnosis accuracy of 62%.
There was no statistically significant difference between fluorocholine PET/CT
and MRI accuracy (P=0.63). On a segment-based analysis, the sensitivity and
specificity were 44% and 82% for fluorocholine PET/CT with diagnosis accuracy of
78%. For MRI, specificity was 91% diagnosis accuracy was 82%.
CONCLUSION: Both MRI and fluorocholine PET/CT permit to highlight local
recurrence sites after prostate brachytherapy. Confirmation biopsies are,
however, necessary since this accuracy is insufficient.
Copyright © 2020 Société française de radiothérapie oncologique (SFRO). Published
by Elsevier Masson SAS. All rights reserved.